The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...

We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

Eli Lilly lost the momentum it had during the first half of the year. However, the company still has plenty of long-term ...

Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The ...

Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

Pfizer also made a fortune with its oral COVID-19 therapy, Paxlovid. Eli Lilly now ranks as the largest drugmaker in the ...

Delving into the details, we found 12% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.